Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen

Acumen Pharmaceuticals (NASDAQ:ABOS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of Acumen Pharmaceuticals in a research report on Thursday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Acumen Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $6.67.

Acumen Pharmaceuticals Stock Down 11.4%

ABOS opened at $2.26 on Friday. Acumen Pharmaceuticals has a 1 year low of $0.86 and a 1 year high of $3.60. The firm has a 50 day moving average price of $2.70 and a 200 day moving average price of $2.16. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The company has a market cap of $136.89 million, a PE ratio of -1.12 and a beta of 0.21.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. The business had revenue of ($0.09) million for the quarter. Sell-side analysts expect that Acumen Pharmaceuticals will post -1.56 earnings per share for the current year.

Insider Buying and Selling

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 37,755 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $1.99, for a total value of $75,132.45. Following the completion of the transaction, the chief executive officer owned 619,982 shares in the company, valued at $1,233,764.18. This represents a 5.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 149,818 shares of company stock worth $285,057. Insiders own 9.30% of the company’s stock.

Institutional Trading of Acumen Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ABOS. Jacobs Levy Equity Management Inc. acquired a new position in shares of Acumen Pharmaceuticals during the third quarter worth $27,000. Marex Group plc purchased a new position in shares of Acumen Pharmaceuticals in the second quarter valued at $39,000. Independent Advisor Alliance acquired a new stake in Acumen Pharmaceuticals during the 4th quarter valued at $40,000. PFG Investments LLC grew its holdings in Acumen Pharmaceuticals by 65.2% during the 4th quarter. PFG Investments LLC now owns 19,000 shares of the company’s stock valued at $40,000 after purchasing an additional 7,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Acumen Pharmaceuticals during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.